193 related articles for article (PubMed ID: 33510588)
21. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
25. Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients.
Lin PT; Teng W; Jeng WJ; Lin CY; Lin SM; Sheen IS
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):213-219. PubMed ID: 33177386
[TBL] [Abstract][Full Text] [Related]
26. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Wang S; Wang Y; Yu J; Wu H; Zhou Y
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428618
[TBL] [Abstract][Full Text] [Related]
28. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
Meyer HJ; Wienke A; Zamsheva M; Surov A
Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
[TBL] [Abstract][Full Text] [Related]
29. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib.
Hsiao YW; Sou FM; Wang JH; Chen YH; Tsai MC; Hu TH; Hung CH; Chen CH; Kuo YH
Kaohsiung J Med Sci; 2023 Dec; 39(12):1233-1242. PubMed ID: 37843189
[TBL] [Abstract][Full Text] [Related]
30. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Xu H; Cao D; Zhou D; Zhao N; Tang X; Shelat VG; Samant H; Satapathy SK; Tustumi F; Aprile G; He A; Xu X; Ge W
BMC Cancer; 2023 Oct; 23(1):1006. PubMed ID: 37858207
[TBL] [Abstract][Full Text] [Related]
31. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
32. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
34. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study.
Chon YE; Kim DY; Kim M; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
Clin Mol Hepatol; 2024 Mar; ():. PubMed ID: 38468561
[TBL] [Abstract][Full Text] [Related]
36. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
37. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
[TBL] [Abstract][Full Text] [Related]
38. Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Chang KV; Chen JD; Wu WT; Huang KC; Hsu CT; Han DS
Liver Cancer; 2018 Mar; 7(1):90-103. PubMed ID: 29662836
[TBL] [Abstract][Full Text] [Related]
39. Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis.
Jiang C; Wang Y; Fu W; Zhang G; Feng X; Wang X; Wang F; Zhang L; Deng Y
Front Nutr; 2022; 9():978110. PubMed ID: 36590214
[TBL] [Abstract][Full Text] [Related]
40. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
